Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).

被引：0
|
作者：
van de Donk, Niels W. C. J.
Garfall, Alfred L.
Benboubker, Lotfi
Uttervall, Katarina
Groen, Kaz
Rosinol, Laura
Matous, Jeffrey V.
Vishwamitra, Deeksha
Hodin, Caroline
Stephenson, Tara
Qi, Keqin
Zuppa, Athena
Chastain, Katherine
Mateos, Maria-Victoria
机构：
[1] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[2] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[3] Ctr Hosp Reg Univ, Hop Bretonneau, Tours, France
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Vrije Univ, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[6] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[7] Colorado Blood Canc Inst, Denver, CO USA
[8] Sarah Cannon Res Inst, Denver, CO USA
[9] Johnson & Johnson Innovat Med, Spring House, PA USA
[10] Johnson & Johnson Innovat Med, Antwerp, Belgium
[11] Johnson & Johnson Innovat Med, Titusville, NJ USA
[12] Johnson & Johnson Innovat Med, Raritan, NJ USA
[13] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Ctr Invest Canc IBMCC USAL, CSIC, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7517
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
    Matous, Jeffrey, V
    van de Donk, Niels W. C. J.
    Oriol, Albert
    Garfall, Alfred L.
    Rodriguez-Otero, Paula
    Chalopin, Thomas
    Dachs, Laura Rosinol
    Uttervall, Katarina
    Mateos, Maria- Victoria
    Trancucci, Danielle
    Carde, Natalia Quijano
    Hodin, Caroline
    Stephenson, Tara
    Zuppa, Athena
    Chastain, Katherine
    Karlin, Lionel
    BLOOD, 2024, 144 : 4749 - 4750
  • [12] Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study
    Nooka, Ajay K.
    Rodriguez, Cesar
    Mateos, Maria Victoria
    Manier, Salomon
    Chastain, Katherine
    Banerjee, Arnob
    Kobos, Rachel
    Qi, Keqin
    Verona, Raluca
    Doyle, Margaret
    Martin, Thomas G.
    van de Donk, Niels W. C. J.
    CANCER, 2024, 130 (06) : 886 - 900
  • [13] Impact of COVID-19 on Outcomes With Teclistamab in the Phase 1/2 MajesTEC-1 Study in Patients With Relapsed/Refractory Multiple Myeloma
    Usmani, Saad
    Bahlis, Nizar J.
    Costa, Luciano
    Mateos Manteca, Maria-Victoria
    Nooka, Ajay
    Perrot, Aurore
    Thaman, Pragya
    Qi, Keqin
    Uhlar, Clarissa
    Chastain, Katherine
    Doyle, Margaret
    van de Donk, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S93 - S93
  • [14] Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
    van de Donk, Niels W. C. J.
    Bahlis, Nizar
    Costa, Luciano J.
    Mateos, Maria-Victoria
    Nooka, Ajay K.
    Perrot, Aurore
    Garfall, Alfred L.
    Thaman, Pragya
    Qi, Keqin
    Uhlar, Clarissa
    Chastain, Katherine
    Doyle, Margaret
    Usmani, Saad Z.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [15] Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study
    Costa, Luciano J.
    Bahlis, Nizar J.
    Usmani, Saad Z.
    van de Donk, Niels W. C. J.
    Nooka, Ajay K.
    Perrot, Aurore
    Qi, Keqin
    Hodin, Caroline
    Uhlar, Clarissa
    Zuppa, Athena
    Chastain, Katherine
    Doyle, Margaret
    Maria-Victoria, Mateos
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S546 - S547
  • [16] Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma
    Vishwamitra, Deeksha
    Skerget, Sheri
    Cortes, Diana
    Perova, Tatiana
    Lau, Onsay
    Davis, Cuc
    Guo, Yue
    Miao, Xin
    Stephenson, Tara
    Hodin, Caroline
    Uhlar, Clarissa
    Trancucci, Danielle
    Chastain, Katherine
    Bahlis, Nizar J.
    Van De Donk, Niels W. C. J.
    Verona, Raluca
    BLOOD, 2023, 142
  • [17] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels
    Moreau, Philippe
    Garfall, Alfred
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay
    Martin, Thomas
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478
  • [18] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Garfall, Alfred L.
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca I.
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
  • [19] Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study
    Schinke, Carolina
    Vij, Ravi
    Jagannath, Sundar
    Sanchez, Larysa
    Pianko, Matthew
    Jakubowiak, Andrzej
    Masterson, Tara J.
    Campagna, Michela
    Zhang, Guoqiang
    Gray, Kathleen
    Renaud, Thomas
    Lau, Bonnie W.
    Morgan, Gareth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S86 - S86
  • [20] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Garfall, Alfred L.
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita Y.
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345